The Shocking Number of Gen Z’ers That Don’t Know Their Credit Score

Credello: A recent survey by found that 42% of Gen Z-ers don’t know their credit scores. Does this mean a major problem for them when it comes time to borrow money, or does it signify a shift in how future generations think about credit?

Why doesn’t Gen Z care about their credit scores?

Generation Z is the newest generation to enter the workforce and is taking a new perspective on how it views financial health. Previous generations saw their credit scores as a top priority for ensuring they could live comfortably.

But after watching the devastating economic fallout Millennials suffered, Gen Z has become more risk-averse to accruing debt. While their elders are searching for credit card refinancing and debt consolidation options, Gen Z’ers seem to be avoiding the idea of borrowing money altogether.

Consequently, the significance of a credit score doesn’t hold as much weight, even though a low score can still affect your chances of renting a home and even entering some career fields. 

So which has to change, Gen Z’s outlook on debt or the world they’re entering?

Despite the interest, their credit scores are good

Interestingly, the data found in their surveys showed that their scores were surprisingly high despite Gen Z having less interest in their credit reports. 54% of those surveyed had credit scores between 799 – 850, averaging higher scores overall than Millennials and Gen X’ers. 

How the financial world is changing

It seems that the financial world is taking this priority shift from the younger generation seriously and is beginning to enact new ways to make credit reporting more relevant with the times:

  • The three main credit bureaus – Equifax, Experian, and TransUnion – have all agreed to remove some instances of medical debt from credit score calculations. 
  • “Buy Now, Pay Later” accounts, popular among younger consumers, will now be included in credit reports.
  • “Trended data” will take a higher priority in scoring calculations, giving your report a more thorough analysis of your buying and spending than the simple “snapshot” currently used.
  • Inclusion of rent, checking and savings account balances, and utility bill or streaming payments as optional data points. Currently, UltraFICO and Experian Boost are adding these as features to boost credit scores of those for whom mortgages and large personal loans are too far out of reach.
  • New scoring models with updated algorithms. Both FICO and VantageScores, the main scoring algorithms used by lenders, have been recently upgraded to account for economic changes and how people spend money.
  • New startup lending companies are leaning into the younger generation’s financial habits by removing the significance of credit scores in their decision-making metrics and relying more on historical spending habits and the average amount of cash on hand. 

The bottom line

While there’s still a long way to go before Gen Z’s credit scores rival those of their elders, these changes show that the world is slowly starting to take them seriously and that it might be the corporations that need to adapt instead of the new consumers.

About Credello

Credello is a financial tech company offering personal finance tools that simplify financial decisions through personalized, on-demand recommendations — so users can borrow, save, or invest with confidence.

Credello believes that finding the right financial product should be as easy and interactive as online shopping, and we are on a mission to make that possible. For more information, please visit

Contact Information:

Keyonda Goosby

Public Relations Specialist

[email protected]

(201) 633-2125

Original Source:

The Shocking Number of Gen Z’ers That Don’t Know Their Credit Score

The post The Shocking Number of Gen Z’ers That Don’t Know Their Credit Score first appeared on RSVTV news.

Sustainalytics Upgrades INNIO Group’s ESG Risk Rating From Low to Negligible Risk, Ranking INNIO Number 1 Worldwide Among Industry Peers

• Sustainalytics ESG rating places INNIO in top 1 percentile of all industry peers and in top 2 percentile of companies rated by Sustainalytics on a global level.

• INNIO receives Sustainalytics’ ESG risk score of 9.8, improving by 11% compared to 2022.

• INNIO also receives Sustainalytics’ 2023 “ESG Industry Top rated” and “ESG Regional Top Rated” badges.

INNIO today announced that Sustainalytics has upgraded INNIO Group’s ESG risk score to 9.8, an improvement of 1.2 points year-over-year, and has upgraded the company’s risk rating from low to negligible. The rating from Sustainalytics, a global leader in ESG research, ratings, and data, reinforces INNIO’s number 1 position compared to peers across both Machinery and Industrial Machinery worldwide.

“Improving our Sustainalytics rating is not only a reflection of our dedication to environmental, social and governance responsibility, it is also a testament to the hard work and collaboration of our talented team,” said Dr. Olaf Berlien, president and CEO of INNIO. “We will continue to prioritize sustainable practices and innovation for the benefit of our business, our stakeholders, and our planet.”

The Sustainalytics risk rating improvement is a vital recognition for INNIO and an indicator of the company’s commitment to sustainable policies and programs. The risk rating focus includes health and safety, environment and carbon management, human capital, procurement practices and circularity. The rating upgrade signals that INNIO’s initiatives and actions to reduce its environmental impact, promote social equity, and ensure good governance are demonstrating positive results. It also underlines INNIO’s commitment to transparency and accountability, which are important factors in building trust and credibility with stakeholders, including customers, suppliers, investors, and employees. 

Learn more about the ESG Risk Ratings.


About Sustainalytics

Sustainalytics is a global leader in ESG research, ratings, and data, serving the world’s leading institutional investors and corporations. Sustainalytics works with hundreds of the world’s leading asset managers and pension funds who incorporate ESG and corporate governance information and assessments into their investment processes. For more information regarding Sustainalytics ESG rating, please visit

About INNIO 

INNIO is a leading energy solution and service provider that empowers industries and communities to make sustainable energy work today. With our product brands Jenbacher and Waukesha and our digital platform myPlant, INNIO offers innovative solutions for the power generation and compression segments that help industries and communities generate and manage energy sustainably while navigating the fast-changing landscape of traditional and green energy sources. We are individual in scope, but global in scale. With our flexible, scalable, and resilient energy solutions and services, we are enabling our customers to manage the energy transition along the energy value chain wherever they are in their transition journey. 

INNIO is headquartered in Jenbach (Austria), with other primary operations in Waukesha (Wisconsin, U.S.) and Welland (Ontario, Canada). A team of more than 4,000 experts provides life-cycle support to the more than 55,000 delivered engines globally through a service network in more than 100 countries. 

INNIO’s improved ESG Risk Rating again secures the number one position across more than 500 companies globally in the machinery industry assessed by Sustainalytics.

For more information, visit INNIO’s website at Follow INNIO on Twitter and LinkedIn.

Contact Information:

Susanne Reichelt

INNIO Media Relations

[email protected]

+43 664 80833 2382

Original Source:

Sustainalytics Upgrades INNIO Group’s ESG Risk Rating From Low to Negligible Risk, Ranking INNIO Number 1 Worldwide Among Industry Peers

The post Sustainalytics Upgrades INNIO Group’s ESG Risk Rating From Low to Negligible Risk, Ranking INNIO Number 1 Worldwide Among Industry Peers first appeared on RSVTV news.

ART MEDICAL Announces Partnership With Teva Israel to Bring Its Lifesaving Technology to Critical Care Units

ART MEDICAL Ltd. is pleased to announce its collaboration with Teva Israel. Under the terms of the agreement, Teva Israel will market and distribute ART MEDICAL’s ground-breaking smART+ Platform in Israel’s intensive care units.

The smART+ Platform is a robotic-assisted technology that aims to reduce complications related to feeding tube malposition, malnutrition, Ventilator-Associated Pneumonia (VAP), and Acute Kidney Injury (AKI). By delivering transformative new-to-the-world data, the smART+ Platform enables medical staff to take a comprehensive approach to critical care, make informed decisions and improve patient outcomes. 

Current related practices in intensive care units rely mostly on manual work and cumbersome procedures. ICU patients are routinely subjected to the risks of malnutrition, tube malposition, and pneumonia. Without technological solutions, nutrition treatment leads to inaccuracies, increased workloads on care teams, and generic nutrition plans that are neither personalized nor updated in real time. The smART+ Platform uses a proprietary sensor-based feeding tube, continuous metabolic assessment, and algorithms, to provide real-time monitoring and closed-loop feedback, resulting in better and personalized care for critically ill patients. 

ART MEDICAL’s Founder and CEO, Liron Elia, says, “Our goal, at ART MEDICAL, is to improve patient outcomes through cutting-edge technology. By integrating real-time data, monitoring, and control mechanisms, the smART+ Platform addresses several of the greatest clinical challenges of intensive care units. This powerful combination provides a comprehensive and innovative nutritional therapy practice as well as optimized care delivery. We are thrilled to partner with Teva Israel to bring our technology to critically ill patients and clinical teams in ICUs.”

Yossi Ofek, GM-Teva Israel, SVP; Cluster Head – Middle East, Africa & Ukraine says:

“Teva Israel continually strives to offer innovative and safe treatment options – both in the community and in hospitals – in order to improve the lives and health of patients.

“The innovative development of an Israeli company, ART MEDICAL, is intended to ensure that patients in intensive care units receive the most advanced treatment offered today that can minimize complications related to hospitalization and reduce length of stay.”

About Teva Israel:

‘Teva Israel’ is the home-based marketing arm of Teva Pharmaceutical Industries Ltd, where it has been working to improve the lives and health of patients, for over 120 years, through high-quality and affordable medicines.

As a leading player in the local health market and particularly in the generics and OTC markets, Teva Israel provides unique services in Israel to Israeli residents, through its logistics company SLE – and markets a wide variety of medicines and products: from original innovative medicines and generic medicines, through medical equipment and devices for hospitals, to over the counter (OTC) medicines and baby milk formula.

Teva Israel is also an innovation incubator for Teva Global and established, in collaboration with Philips, Sanara Ventures, a platform for investments in start-up companies in the fields of digital medicine and medical devices. In Israel, one of every four prescriptions is for a Teva drug, while the annual savings that the company’s generic drugs bring to the Israeli healthcare system is estimated at about one and a half billion shekels, per year.


ART MEDICAL is on a mission to save lives through technological innovations and redefine the future of critical care. Our goal is to see ICU patients get better faster with the help of real-time nutrition management. Visit or follow us on LinkedIn for more information. 

Forward-Looking Statements of ART MEDICAL

ART MEDICAL developed the smART+™ Platform as a holistic approach for the next-generation ICU, featuring an ecosystem of sensor-based tools, software, and algorithms. smART+ is designed to prevent ICU-acquired complications. The smART+ Platform aims to reduce length of ventilation days and length of stay that are attributed to malnutrition, VAP, and other secondary infections and complications, ultimately providing better care, and dramatically reducing healthcare costs.



Contact Information:

Ori Braun

SVP Business Development

[email protected]

Original Source:

ART MEDICAL Announces Partnership With Teva Israel to Bring Its Lifesaving Technology to Critical Care Units